Stay updated on Ad-p53+Xeloda/Anti-PD-1 Safety/Efficacy in Liver Metastases Clinical Trial
Sign up to get notified when there's something new on the Ad-p53+Xeloda/Anti-PD-1 Safety/Efficacy in Liver Metastases Clinical Trial page.

Latest updates to the Ad-p53+Xeloda/Anti-PD-1 Safety/Efficacy in Liver Metastases Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe web page has undergone significant changes, including the removal of detailed descriptions of a Phase 1/2 study involving Ad-p53 and various treatment combinations for metastatic cancers, while adding a new version revision and a mention of the study's location.SummaryDifference45%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check38 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check74 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check88 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
Stay in the know with updates to Ad-p53+Xeloda/Anti-PD-1 Safety/Efficacy in Liver Metastases Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ad-p53+Xeloda/Anti-PD-1 Safety/Efficacy in Liver Metastases Clinical Trial page.